Case Studies, Pharmaceutical

Case Study – Bidose Nasal Spray Pump for Depression

Treatment resistant depression (TRD) affects 1 in 3 sufferers of depression creating an urgent need for therapeutics that differ in action to conventional anti-depressants. This case study describes a collaborative project to develop an esketamine nasal spray to meet this demand. The developed product utilizes Aptar Pharma’s patented Bidose nasal spray pump to deliver two subsequent drug doses, providing patients with a non-invasive, self-administered option for treatment. Use is heavily regulated due to the addictive nature of esketamine but the product has delivered promising results when used in combination with oral anti-depressants. Formulation as a nasal spray exploits recognized potential for ‘nose to brain’ drug delivery and has proven effective in minimizing side effects. The product is a first-in-class solution for TRD and was recognized as one of the top new drugs of 2019 with respect to sales potential.

Download Case Study - Bidose Nasal Spray Pump for Depression
8 Sep 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

24 Apr 2024

Advancing OINDP Clinical Trials with Speed and Efficiency: Strategies for Success

Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Market Insights

Read More
24 Apr 2024

Exploring Nasal Casts in Nasal Drug Development

Publications, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights

Read More
3 Apr 2024

Delivering Nasally Administered Biologics

Webinars, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights, Device Innovations

Read More
3 Apr 2024

Nasal Casts, Tools to Enable Nasal Drug Delivery Development

Webinars, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
1 2 3 25

Request Access


Requesting access to Case Study – Bidose Nasal Spray Pump for Depression.

  • This field is for validation purposes and should be left unchanged.
Back To Top